https://www.frenchstemtoday.com/article/905963305-theom-redefines-ai-data-security-placing-as-a-leader-across-major-industry-analyst-evaluations French STEM Today en PressRelease 2026-04-24T15:51:15+00:00 Theom Redefines AI & Data Security, Placing as a Leader Across Major Industry Analyst Evaluations https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24838636-logo-with-tagline-4050x1796.png https://www.frenchstemtoday.com/article/907333521-vera-co-founder-julie-cropp-gareleck-featured-as-a-leading-voice-on-people-first-ai-and-workforce-transformation French STEM Today en PressRelease 2026-04-23T10:00:00+00:00 Vera Co-Founder Julie Cropp Gareleck Featured as a Leading Voice on People-First AI and Workforce Transformation https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/23803362-vera-corporate-company-logo-3333x2500.jpeg https://www.frenchstemtoday.com/article/907490040-last-patient-last-visit-completed-in-phase-i-clinical-trial-of-pulsesight-therapeutics-pst-611-treatment-for-dry-amd-geographic-atrophy-ga French STEM Today en PressRelease 2026-04-23T07:00:00+00:00 Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA) https://ml-eu.globenewswire.com/media/9f8ee53c-2465-4c3c-870e-4077c6a39edb/small/pulsesight-therapeutics-logo-horizontal-full-gradient-mark-0.png https://www.frenchstemtoday.com/article/907472537-ose-immunotherapeutics-annonce-la-pr-sentation-des-r-sultats-de-l-tude-de-phase-2-tedova-de-tedopi-dans-le-cancer-de-l-ovaire-au-congr-s-2026-de French STEM Today en PressRelease 2026-04-23T05:30:00+00:00 OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.frenchstemtoday.com/article/907472829-ose-immunotherapeutics-announces-presentation-of-tedova-phase-2-topline-results-of-tedopi-in-ovarian-cancer-at-the-asco-2026-meeting French STEM Today en PressRelease 2026-04-23T05:30:00+00:00 OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png